[HTML][HTML] The off-label use of four-factor prothrombin complex concentrate: a single institution retrospective study
Abstract Background/Introduction: 4-factor prothrombin complex concentrate (PCC) is
currently approved in the United States for the urgent reversal of warfarin-induced …
currently approved in the United States for the urgent reversal of warfarin-induced …
Off‐label use of 4‐factor prothrombin complex concentrate is common despite little known benefit: a retrospective study
CD Scharman, JJ Shatzel, E Kim… - European Journal of …, 2018 - Wiley Online Library
Abstract Background/Objective While four‐factor prothrombin complex concentrate (4F‐
PCC) is FDA‐approved for reversal of warfarin‐induced major bleeding, its use in real‐world …
PCC) is FDA‐approved for reversal of warfarin‐induced major bleeding, its use in real‐world …
Fixed-dose 4-factor prothrombin complex concentrate: we don't know where we're going if we don't know how to get there
ST Hall, KC Molina - Journal of Thrombosis and Thrombolysis, 2018 - Springer
Factor Prothrombin Complex Concentrate (4F-PCC) is the standard-of-care intervention in
patients with major bleeding taking oral vitamin K antagonists. Despite growing clinical …
patients with major bleeding taking oral vitamin K antagonists. Despite growing clinical …
[PDF][PDF] Efficacy and Safety of a Four-Factor Prothrombin Complex Concentrate (4F-PCC) in Patients on Vitamin K Antagonists Presenting with Major Bleeding: A …
R Sarode, TJ Milling Jr, MA Refaai, A Mangione… - Citeseer
Background—Patients experiencing major bleeding while taking vitamin K antagonists
(VKAs) require rapid VKA reversal. We performed a prospective clinical trial to compare non …
(VKAs) require rapid VKA reversal. We performed a prospective clinical trial to compare non …
On‐label compared to off‐label four‐factor prothrombin complex concentrate use: a retrospective, observational study
BC Cho, YH Jung, VM DeMario, E Lau… - …, 2019 - Wiley Online Library
BACKGROUND Four‐factor prothrombin complex concentrate (4F‐PCC) is US Food and
Drug Administration approved for the urgent reversal of coagulation factor deficiency …
Drug Administration approved for the urgent reversal of coagulation factor deficiency …
Four-factor prothrombin complex concentrate use for on-label versus off-label indications: a retrospective cohort study
BD Adkins, H Shaim, A Abid, A Gonzalez… - Journal of Thrombosis …, 2023 - Springer
This study aimed to characterize the utilization of four-factor prothrombin complex
concentrate (4F-PCC) at a tertiary academic medical center and evaluate the incidence of …
concentrate (4F-PCC) at a tertiary academic medical center and evaluate the incidence of …
[HTML][HTML] Clinical utilization of four-factor prothrombin complex concentrate: a retrospective single center study
Z Naeem, S Allan, A Hernandez… - Clinical and …, 2021 - ncbi.nlm.nih.gov
Objective Four-factor prothrombin complex concentrate (4F-PCC) was approved by the US
Food and Drug Administration in 2013 for management of severely bleeding patients on …
Food and Drug Administration in 2013 for management of severely bleeding patients on …
Comparison of the safety and efficacy between 3-factor and 4-factor prothrombin complex concentrates for the reversal of warfarin
JE Kuroski, S Young - The American Journal of Emergency Medicine, 2017 - Elsevier
Abstract Purpose Prior to the Food and Drug Administration approval of 4-factor prothrombin
complex concentrate (4F-PCC), only 3-factor PCC (3F-PCC) products were available in the …
complex concentrate (4F-PCC), only 3-factor PCC (3F-PCC) products were available in the …
3-Factor versus 4-factor prothrombin complex concentrate for warfarin reversal in severe bleeding: a multicenter, retrospective, propensity-matched pilot study
GM Jones, MJ Erdman, KS Smetana… - Journal of thrombosis …, 2016 - Springer
Current guidelines recommend 4-factor prothrombin complex concentrate (4PCC) for
emergent reversal of bleeding secondary to warfarin. While current research has …
emergent reversal of bleeding secondary to warfarin. While current research has …
Comparison of hemostatic outcomes in patients receiving fixed-dose vs. weight-based 4-factor prothrombin complex concentrate
C Kim, L Cottingham, K Eberwein, K Komyathy… - The Journal of …, 2020 - Elsevier
Background Four-factor prothrombin complex concentrate (4F-PCC) is a blood coagulation
product indicated for urgent reversal of warfarin. Currently there are no studies using 4F …
product indicated for urgent reversal of warfarin. Currently there are no studies using 4F …